Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
8 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Intuitive Surgical reported Q3 2026 revenue growth of 22% to over $3 billion, alongside 15% growth in total procedures and 28% growth in da Vinci system placements. The company also plans to reduce da Vinci instruments and accessories revenue per procedure by 3% to 5%.
Oncology Institute reported Q2 revenue of approximately $161 million, up 35% year over year, and positive adjusted EBITDA. It raised full-year revenue guidance to $650–670 million and gross profit guidance to $105–110 million.
HIVE Digital Technologies (NASDAQ: HIVE ) held its first-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary HIVE Digital Technologies reported a 73% year-over-year r
A new global survey from Modern Health reveals 71% of employees link seeking care to workplace stress, while 60% believe there's over-reliance on therapy. Employers are financing a level of care many workers feel exceeds their actual needs.
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04, the S&P 500 advancing 1.14% to 7,637.76 and the Nasdaq climbing 1.69% to 26,418.29. These are the top stocks that gained the attention of retail traders and investors through the day: Aethlon Medical Inc. (NAS
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
John Wiley & Sons said Q1 Research publishing revenue rose 12%, while Learning revenue fell 20%. The company reiterated full-year guidance for mid-single-digit organic revenue growth, adjusted EPS of $4.60 to $5.05 and free cash flow of $205 million.
Cancer treatment costs expected to increase, affecting healthcare expenses. ACA could have mitigated costs for some patients.